Last updated: March 13, 2026
What is the drug identified by NDC 72305-0137?
The drug with NDC 72305-0137 is Zolgensma (onasemnogene abeparvovec-xioi), developed by Novartis. It is a gene therapy approved by the U.S. Food and Drug Administration (FDA) in May 2019 for the treatment of spinal muscular atrophy (SMA) in pediatric patients under 2 years old. It is administered as a one-time intravenous infusion. Zolgensma delivers a functional copy of the human SMN gene, addressing the genetic cause of SMA.
Market Overview
Patient Population
SMA affects approximately 1 in 10,000 live births globally, with an incidence of roughly 1 in 6,000 to 1 in 10,000. In the U.S., approximately 400 to 500 infants are diagnosed annually. The target demographic is pediatric patients under age 2, with the potential for treated patients surviving longer, enhancing the therapy's market size over time.
Competitive Landscape
Zolgensma faces competition primarily from:
- Spinraza (nusinersen) by Biogen: Approved in 2016, administered via intrathecal injection. It has a market share due to earlier market entry.
- Evrysdi (risdiplam) by Roche: Approved in 2020, administered orally, expanding options for SMA treatment.
The accelerated adoption of gene therapy depends on factors such as efficacy, safety profile, administration complexity, and payer coverage.
Market Dynamics
Treatment Adoption Trends
- Early adoption: Driven by newness and potential for a one-time cure.
- Pricing negotiations: Driven by healthcare payers seeking value, considering the therapy's high upfront cost.
Reimbursement Environment
Coverage is primarily managed through national health services and private insurers. Reimbursement decisions hinge on demonstrated efficacy, safety data, and cost-effectiveness models.
Global Market Potential
Primarily in high-income countries with established healthcare reimbursement systems. Emerging markets are adopting later, constrained by cost and infrastructure for gene therapy administration.
Price Projections
Current Cost
- List price: $2.1 million per infusion in the U.S. (Novartis official prices, 2022).
- Cost considerations: Includes manufacturing, administration, and post-treatment monitoring.
Short-term Projections (Next 2-3 Years)
- The list price is expected to remain around $2.1 million, with little variation.
- Payer negotiations may reduce actual reimbursed amount by 10-20%, resulting in effective prices of approximately $1.7-$2 million.
- Increase in volume is projected as approval expands to older children and cases in emerging markets.
Long-term Price Trends (Next 5-10 Years)
- Competition and biosimilar development are limited due to the nature of gene therapies, suggesting stable high pricing.
- Parallel advancements in gene-editing technologies may influence future costs and formulations.
- Patent protections typically extend until 2030, providing a revenue window of at least 8 more years without biosimilar competition.
Market Penetration & Revenue Estimate (2023-2030)
| Year |
Estimated Patients Treated |
Revenue Estimate (USD millions) |
| 2023 |
500 |
1,050 (~$2.1M per patient) |
| 2025 |
1,500 |
3,150 |
| 2030 |
2,500 |
5,250 |
Assumptions:
- Growing diagnoses and approval expansion.
- Market share rising with increasing adoption and payer acceptance.
- Stable pricing with minor adjustments for inflation or negotiations.
Pricing & Regulatory Challenges
- High upfront costs impose burden on health systems.
- Payer resistance may influence concessions.
- Long-term safety and efficacy data will impact willingness to pay at current prices.
- Market access varies globally; regulatory hurdles can delay or limit commercialization.
Investment & Business Implications
- Limited competition suggests sustained pricing power until 2030.
- Patent expiry, biosimilar development, or new treatment paradigms could compress margins post-2030.
- Manufacturing complexity and distribution logistics pose entry barriers for new competitors.
Key Takeaways
- NDC 72305-0137 refers to Zolgensma, a gene therapy for SMA, with a current list price of approximately $2.1 million.
- The market is driven by a small patient base but high treatment value; demand is expected to grow steadily.
- Long-term pricing stability is likely until patent expiration, with moderate negotiation-driven discounts.
- Competition from other SMA treatments exists but may not significantly impact pricing until biosimilar-like developments occur.
- Market expansion into older patients and emerging regions could increase revenues modestly.
FAQs
Q1. Is Zolgensma priced competitively with other SMA treatments?
A1. Its list price is higher than Spinraza and Evrysdi. However, it offers the benefit of a single administration, which some payers find valuable.
Q2. What factors could influence future price reductions?
A2. Biosimilar development, market saturation, or regulatory changes could lead to price pressure.
Q3. How does the manufacturing complexity impact pricing?
A3. The complexity and novelty of gene therapy manufacturing justify high prices; reductions would require process innovations.
Q4. Are there accelerations in market expansion?
A4. Yes. Expanding approval to older children and global markets will likely grow the market size.
Q5. What is the patent status for Zolgensma?
A5. Patent protections extend until around 2030, enabling market exclusivity during this period.
References
[1] FDA. (2019). Zolgensma (onasemnogene abeparvovec-xioi) approval.
[2] Novartis. (2022). Price list for Zolgensma.
[3] MarketWatch. (2023). Gene therapy market analysis.
[4] EvaluatePharma. (2022). Biopharmaceutical pricing trends.
[5] GlobalData. (2022). SMA treatment market forecast.
